The Oregon Clinical & Translational Research Institute at OHSU has received a $37 million boost from the federal government to help accelerate the translation of research into clinical use, medical practice and health policy.
The first FDA-approved gene transfer therapy for patients with acute lymphoblastic leukemia will be available at a handful of approved hospitals, including OHSU Doernbecher.
Scientists have uncovered two related cytokines and associated genetic markers that may explain why some people develop progressive multiple sclerosis, or MS.
OHSU Hospital ranks 12th in the nation for “superior performance" in providing high-quality care, based on mortality, safety, efficiency, effectiveness, patient centeredness and equity, according to the 2017 Vizient Quality and Accountability Study.